Form 4 for IONS IONIS PHARMACEUTICALS INC
Accepted 2024-01-17 00:00:00 ET · period of report 2024-01-12 · accession 0000874015-24-000059 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2024-01-17 | 2024-01-12 | IONS | Schneider Eugene | EVP, Chf Clinical Develop Ofcr | M - OptEx | $32.60 | +8,000 | 46.2K | +21% | +$260.8K |
| D | 2024-01-17 | 2024-01-12 | IONS | Schneider Eugene | EVP, Chf Clinical Develop Ofcr | S - Sale+OE | $53.50 | -8,000 | 38.2K | -17% | -$428.0K |
| D | 2024-01-17 | 2024-01-12 | IONS | Schneider Eugene | EVP, Chf Clinical Develop Ofcr | M - OptEx | $0.00 | -8,000 | 24.3K | -25% | $0 |
| DM | 2024-01-17 | 2024-01-15 | IONS | Schneider Eugene | EVP, Chf Clinical Develop Ofcr | A - Grant | $0.00 | +37.4K | 60.5K | +162% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-01-12 | M | A | 8,000 | $32.60 | 46,170 | D | — | — | |
| 2 | Common | Common Stock | 2024-01-12 | S | D | 8,000 | $53.50 | 38,170 | D | — | — | |
| 3 | Derivative | Non-Qualified Stock Option (right to buy) | 2024-01-12 | M | D | 8,000 | $0.00 | 24,265 | D | $32.60 · 2023-01-03 to 2032-01-02 | 8,000 Common Stock | |
| 4 | Derivative | Performance Restricted Stock Units | 2024-01-15 | A | A | 17,000 | $0.00 | 43,437 | D | $0.00 · — to — | 17,000 Common Stock | (F1) Grant to reporting person of Performance Restricted Stock Units (PRSUs) under the Ionis Pharmaceuticals, Inc. Amended and Restated 2011 Equity Incentive Plan. (F2) The PRSUs may vest at the end of the three-year performance period following the date of grant based on the Issuer's relative total shareholder return as compared to a peer group of companies. The number of PRSUs reported represents the maximum that may be earned, which is 200% of the target number. No number of PRSUs is guaranteed to vest and the actual number of PRSUs that will vest at the end of the performance period may be anywhere from zero to the amount stated. |
| 5 | Derivative | Restricted Stock Unit | 2024-01-15 | A | A | 20,400 | $0.00 | 60,470 | D | $0.00 · — to — | 20,400 Common Stock | (F3) Grant to reporting person of Restricted Stock Units under the Ionis Pharmaceuticals, Inc. Amended and Restated 2011 Equity Incentive Plan. (F4) Each Restricted Stock Unit represents a contingent right to receive one share of Ionis common stock, or its equivalent cash value. (F5) Restricted Stock Units vest in four equal annual installments. Upon vesting, the restricted stock units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company. |